Company intelligence / Profile preview

Epiontis

Berlin, Berlin, Germanyprecisionformedicine.com ↗

Ownership: Private
Development stage: Commercial

Overview

Epiontis developed and commercialized the proprietary Epiontis ID® technology—a robust epigenetic qPCR-based method for precise quantification of immune cell subsets from diverse sample types. The service has been used in over 100 clinical studies as a secondary outcome measure and has analyzed more than 100,000 samples. Data generated are routinely included in peer-reviewed publications. The company was acquired by Precision for Medicine in October 2017 to expand global capabilities in immune monitoring.

Therapeutic areas: OncologyImmunology
Modalities: Diagnostic assay (epigenetic qPCR-based immune cell profiling)Biomarker assay solutions
Industry: Molecular Diagnostics

Partnerships

Provided services to at least "17 of the top 20 global pharmaceutical companies" as clients

Beyond the preview

Go deeper on Epiontis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Epiontis.

Explore the full profile